Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING EDUCATION CREDIT (Pharmacists, Nurses, Nurse Practitioners, and Physician Assistants):
You will receive a certificate of attendance for the CME-certified sessions (those designated for AMA/PRA Category 1 Credits™) which may be submitted to state licensing boards for determination of credit reciprocity (conversion to CEUs).
Acknowledgment of Commercial SupportThis activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
7:00 PM - 8:30 PM (Registration and Dinner 6:30 PM - 7:00 PM)
The Grand America Hotel (Grand Ballroom B & C; located on the Lobby Level of Hotel)
555 Main St, Salt Lake City, UT
Breakthroughs in Soft Tissue Sarcoma: Perspectives on Emerging Strategies is a CME-certified live symposium to be held adjunct to the annual sarcoma meeting in Salt Lake City, Utah.
There is a substantial need for improved strategies to manage soft tissue sarcoma (STS). These tumors are heterogeneous malignancies characterized by a complex histology and molecular mutations. Advanced forms of these tumors are especially challenging to manage. Optimal treatment requires a highly skilled, multidisciplinary team including medicine, pathology, radiology, and surgery. Novel strategies for these tumors are in late-stage clinical development and may represent significant steps forward for patients with these most difficult-to-treat tumors. This activity will meet the educational needs of oncology healthcare professionals to keep them up to date on state-of-the-art therapeutic strategies to manage patients with STS.
Please join us and a renowned group of sarcoma experts on Thursday, November 5, from 6:30 pm-8:30 pm to learn about breakthroughs occurring in the treatment and management of STS. This program is not to be missed by clinicians interested in the treatment of this form of cancer.
Key topics on the agenda include:
- Methods to optimize multimodality management from diagnosis along the continuum of care
- Practice-changing clinical trial data in the settings of metastatic and unresectable STS
- Strategies to apply emerging landmark findings to real-world clinical practice scenarios in patients with advanced disease
- Addressing important clinical questions that remain in the field to optimize outcomes
This educational program is directed toward medical oncologists, surgical oncologists, radiation oncologists, and researchers interested in the treatment of STS. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with sarcoma will be invited to participate.
Upon completion of this activity, participants will be able to:
- Discuss contemporary multidisciplinary strategies utilized in the management of advanced forms of STS
- Explain novel mechanistic approaches under investigation for the treatment of patients with metastatic or unresectable STS
- Evaluate emerging clinical trial results in the context of evolving treatment paradigms in STS and multimodality sequencing in multiple lines of care
George D. Demetri, MD
Professor of Medicine, Harvard Medical School
Director, Ludwig Center at Harvard
Director, Center for Sarcoma and Bone Oncology
Dana-Farber Cancer Institute
Robin L. Jones, BSc, MB, MRCP, MD (Res)
Royal Marsden Hospital
Team Leader, Sarcoma Clinical Trials
Institute of Cancer Research
William D. Tap, MD
Chief, Sarcoma Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY